Madrigal Pharmaceuticals Inc (MDGL) Quote

I think MDGL needs to make a strategic move and build the pipeline someone will will buy SGMT sooner than later Thierry the CFO at Sagimet has tentacles around the pharma sector. I think LLY Novo or Gilead or AMGN sneak in and make a strategic move with sgmt.
The street not impressed with the F4 data nearly 40% of the patients had diarrhea. This way they can bullet proof the nash space and then be able to enter the obesity market with FASN fat synthesis THR Beta combination single oral tablets and or triple tablet GLP1 FASN and THR Beta I can't believe SGMT hasn't been bought out with Break Through designation for MASH 3100 Patients Phase 3's.

$MDGL

"MASLD" and "MASH" are new terms for previously known conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), respectively. The name change reflects a shift in understanding the causes of these liver conditions, with a greater emphasis on metabolic dysfunction as a primary driver.
MASH: A More Severe Form of MASLD

MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease):
.

This umbrella term describes fatty liver disease where fat accumulates in the liver due to factors like obesity, type 2 diabetes, or high blood pressure.
MASH (Metabolic Dysfunction-Associated Steatohepatitis):
.
A more advanced stage of MASLD where the fat buildup has led to inflammation, liver damage, and in some cases, scarring (fibrosis).

Growing Concern: The Increasing Prevalence of MASLD and MASH

MASLD is a major global health concern, with a rapidly increasing prevalence worldwide.

The rising rates of obesity, type 2 diabetes, and metabolic syndrome are major contributors to the growth of MASLD and MASH.
MASH is projected to become a leading cause of liver transplants and cirrhosis in the United States.
The potential for liver cancer (hepatocellular carcinoma) is a serious complication of MASLD, particularly with advanced fibrosis or cirrhosis.

Key Takeaways

MASLD and MASH are significant and growing health problems, especially in regions with high rates of obesity and metabolic disorders.

Early detection and management of MASLD and MASH are crucial to prevent progression to more severe forms of liver disease, such as cirrhosis and liver cancer.
Lifestyle changes, including weight loss, healthy eating, and regular physical activity, can be effective in managing MASLD and MASH.
If you are concerned about your risk for MASLD or MASH, it's important to consult with a healthcare professional for proper evaluation and management.

Metabolic dysfunction-associated steatohepatitis (MASH)
MASLD is an umbrella term for conditions caused by the build-up of extra fat in the liver that is not caused by alcohol intake. As...
Novo Nordisk

Nonalcoholic fatty liver disease - Symptoms and causes - Mayo Clinic
Apr 4, 2024 — NASH causes the liver to swell and become damaged due to the fat deposits in the liver. NASH may get worse and may lead...
Mayo Clinic
Nonalcoholic Fatty Liver Disease - Johns Hopkins Medicine
Based on the test results, your healthcare provider will make the following diagnosis: * You have MASLD if you have fat but no in...
Johns Hopkins Medicine

Show all

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes.
Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F=F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity
https://www.cnbc.com/video/2025/02/26/madrigal-ceo-on-q4-earnings-beat-mash-drug-market-opportunity.html

$MDGL

IP goes to SGMT good through 2048 this is going to be 1 tablet combo of the two drugs looks like M&A has started.
Combination of denifanstat and resmetirom (MDGL):
• Application filed 2024; if granted—2044; potential PTE to 2048

Combination of fatty acid synthase (FASN) inhibitor and Madrigal's thyroid hormone receptor beta (THRb) agonist resmetirom shows
synergistic improvement of NAFLD activity score (NAS) within 6-weeks
in diet-induced obese mice with biopsy-confirmed MASH
33% FASN
23% Resmetirom
80% Combo of the two drugs improved each component of NAFLD

$MDGL

Started to Nibble on some madrigal options late 2025 holding my core position from the 70.00's AKRO shit data makes MDGL more valuable.
Interesting Madrigal and Sagimet doing a single pill combo of their two drugs soon. Does Madrigal take out Sagimet or does a bigger player show up Bill Sibold Deeper pocket BP like LLY Gilead Novo or Novartis can scoop up on SGMT and not even Flinch they have the best looking oral in the space that works wonders with ThR B and GLP1 like Ozempic in combos a blockbuster stand alone first Line F2 F3 & F4 and a blockbuster for combos with GLp1 42% fibrosis reduction vs 0% in placebo.

$MDGL

MDGL under $350

Combination of fatty acid synthase (FASN) (SGMT) inhibitor and thyroid hormone receptor beta (THRb) agonist MDGL resmetirom shows
synergistic improvement of NAFLD activity score (NAS) within 6-weeks by 80% in combination
in diet-induced obese mice with biopsy-confirmed MASH
https://sagimet.com/wp-content/uploads/2024/06/2024-EASL-poster-GAN-model-final.pdf

Who is MDGL going to partner with or buy to expand their pipeline!
My guess Madrigal does something SGMT and then Sanofi buys MDGL!
$MDGL

Madrigal most likely will announce a partnership or buyout to strengthen their pipeline. I think SGMT is a logical choice.

Their fat synthesizer enhances the efficacy of Rezdiffra (resmetirom) when in combo with Denifanstat off the Charts results.

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

EASL International Liver Congress
Date - 06/2024
poster
Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor .
knockout MASH mice.

I started buying MDGL at $70 a few years ago when everyone was talking it down!



$MDGL

shorts are about to get obliterated core Holding in since $70.00 not selling any shares till $750.00

Thanks!

Nice pickup! Congrats

Bought some $MDGL on the dip today ahead of March 14th FDA meeting

MDGL’s CEO and CCO both resigned during_the_past_two_weeks—what’s up?

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001157601/000119312523234395/d444513d8k.htm (CEO)

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001157601/000119312523241315/d684437d8k.htm (CCO)

Just bought 20 shares at 192. Scaling back in after being in it ahead of December's big move and selling. Hopefully things go well here and we get FDA approval and a buyout eventually

$MDGL: HEPA is the Cheapest value in NASH space

If you really love the NASH space.

Doesn't get better than that and HEPA competes HEAD ON with MDGL in the same space.


Other than that.............. never heard of you here before so, whatever


GO $MDGL

$500 will be here soon enough!

$MDGL

Riding free shares 300% profits last week was holding for 6 months worth the wait being patient & nailed some of the Jan 2023 calls a few weeks ago. It's going to go higher! 300 Million in financing to complete remaining trails Nash market is worth tens of Billions of dollars should be years ahead of the rest. Look for Buyout in 2023.

$MDGL

Moew like $185.

$MDGL: Largest OI right now is Jan20,2023 $120puts

Currently at 0.30


MDGL management would be idiots if they didn't do a Secondary OFFERING now to collect some easy cash.

Im starting to look at these contracts, getting pretty tempting


GO $MDGL

$MDGL: WOW ..... 315......... going to $400 ???

Won't shock me at all if and when it happens


Seen this happen before on $ICPT


GO $MDGL

$MDGL: Killing it now......... OVER 300 !!!!!!!!!!!!

Without a doubt.................. , the BEST STOCK OF THE WEEK ANYWHERE.

And theres only how many, 3 of us here

Only ballers here

Can't believe $HEPA hasnt boosted here and its all in the NASH space like $MDGL.
Even VKTX in the NASH space is getting a boost from MDGL.
$HEPA should be over a $1 with this MDGL draftwinds


WOW


GO $MDGL

Wait, is this ganna create sell off tomorrow?

4:19
News Detail
TI
Madrigal Pharmaceuticals raised $239 ml in gross equity from equity securities issuances and additional $50 mln in liquidity commitments
4:18 PM ET 12/21/2022 | Briefing.com
MDGL
Co announces that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit
Facility.Madrigal has completed $159 million in gross sales of common stock under its ATM Program ("ATM
Sales") and has separately entered into a $100 million definitive securities purchase agreement with two of its existing institutional investors for the purchase of $90 million in shares of Series B Convertible Preferred
Stock (the "Series B") and $10 million in shares of the Company's common stock.In connection with Madrigal's December 19, 2022 announcement of positive topline data from its pivotal Phase 3
MAESTRO-NASH clinical trial of resmetirom, Hercules Capital, Inc. (HTGC) confirmed that Madrigal has achieved its clinical milestone under the Company's Credit Facility with Hercules, thereby enabling Madrigal to draw upon a $50 million clinical milestone tranche over the next three months.

Oh, well

There are no set rules regarding how long a short sale can last before being closed out. The lender of the shorted shares can request that the shares be returned by the investor at any time, with minimal notice, but this rarely happens in practice so long as the short seller keeps paying their margin interest.

Shorting stocks should be more strict than this….

I am sure a lot of traders are shorting MDGL already. How soon do they have to cover the short? Do you know?

$MDGL: JUst amazing now............ 275 !!!!!!!!!!


WOW......... still no offfering.

This is sooooooooooooo incredible.


Those Calls are now $168 !!!!!!!!!!!!!

WOW....... they were only $13 last week


AMAZZZZZZZZZZINGGGGGGGGGGGGGGGGGGGGGGGgg


Reminds me of the boost in $ICPT several years ago


GO $MDGL

MDGL might be holding well because smart investors know FDA approval is imminent or merger and buyout. I am expecting much higher price or the deal.

$MDGL has $49.81M DEBT, Book value is only $.62

MDGL > 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo
NASH resolution (ballooning of 0, inflammation of 0-1) and greater-than or equal to2-point NAS reduction with no worsening of fibrosis (p<0.0001 at both doses)
Fibrosis improvement by at least one stage with no worsening of NAS (p=0.0002 and <0.0001 at 80 and 100 mg, respectively)
Potentially clinically meaningful LDL-lowering, a key secondary endpoint (p<0.0001)
Multiple positive effects on NASH biomarkers and imaging
Resmetirom was safe and well-tolerated in the MAESTRO-NASH study, consistent with the overall safety in Phase 3 MAESTRO trials, expanding the large safety database
Madrigal intends to file a new drug application seeking accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with liver fibrosis

$MDGL: Thanks for that......... I hope AADI

Has a similar Stratospheric BOOST like $MDGL just did.


Congrats on that MEGA WINNER


Merry XMAS


GO $MDGL

I saw your post sent you a heads up

$MDGL : Some genius grabbed 3200 Jan2023 $100calls on Thursday

WOW............... Those are up massive now.


Premium was at $13 on Friday last week........... now at $115


AMAZING


GO $MDGL

Just in case 87 went to 220

87 today as well lol. I knew I should have sold half once it past $90

$87 today
Looks like the big guys had their specialist look at those Phase III results and see something good. NASH is a disease with no approved treatment. Last drug to go before an Advisory Panel was denied because benefit did not outweigh the risk.
Madrigals big phase III safety trial just passed with flying colors. Folks looking to get in ahead of the FDA awarded "accelerated approval" status.

Keeps inching up

Iook like earnings or something coming end of feb. Maybe a fire will be lit then

Now its getting attention.

Share price could care less tho lol

Great news today!

News in the AM, pre announced today... see if I can get some premarket shares

Piper Sandler presentation
60mg dose not in phase 3 showed 19% NASH Resolution
80 mg dose in phase 2 trial = 38% resolution
Better is that the phase 3 trial has a 100mg arm and with the safety data coming in it looks like the ideal dose for an even higher resolution percentage.

Also, the company has been in talks with multiple Big Pharma about partnering. Madrigal feel confident enough that they feel no partnering will take place until after the final phase 3 data is presented in 2022.

Glad this one is off the radar and may give me another chance to add shares at lower prices.

Madrigal at 52 week lows because it is off the radar
Phase 3 NAFLD results coming soon and I'll be looking for a clean safety profile and indications nonintrusive biomarkers can be used to follow therapy and to diagnose NASH (not NAFLD).

Looking back at Phase 2 results confirmed with biopsy in NASH phase 2 trial
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints

Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy --

-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved resolution of NASH on biopsy --

Current phase 3 trial will dose 52 weeks not the 36 weeks in the phase 2 trial. The current phase 3 trial will also be based on higher doses that were much more effective at reducing liver fat by >50%. 50% liver fat reduction is considered ideal to see liver improvement.

Two phase 3 trials with focus on NASH. NAFLD arm will likely be difficult to show improvement over placebo in a short term trial. The NAFLD news coming soon is an expected buying op for me as the headliner will be about treating NAFLD for 52 weeks probably being the headline and an op for Wall Street to attack the price so that they can collect cheaper shares before NASH results next year.

I heard there was news today but I can’t find it. Anyone know of anything?

BioVie is unbelievably way under-the-radar. It is the most undervalued NASH related stock you can find in the market. Mr. Terren Peizer saw the great potential of this company, not to mention Mallinckrodt's (MNK) interest on BioVie's Technology Platform, thus initiating a IP patent challenge with the USPTO which I think the deciding factor that led him to embark in this microcap company. Considering his profile, I believe BioVie is in good hands. All this in my opinion only.

BioVie, Inc. (BIVI)
Pioneering therapies for advanced liver disease
Non-confidential investor presentation | December 2018

***A new treatment option is emerging for refractory ascites
Based on investigative studies in Italy and Australia
***Terlipressin (BIV201’s active agent) is approved in 40+ countries for
treating related liver cirrhosis complications (HRS & BEV*)

***BIV201 is a new drug candidate in the US
Terlipressin is not available in the US or Japan

***Currently in US phase 2 clinical
trials; seeking to replicate
European & Australian
investigative study results

***BIV201 offers advantages in 40+ countries where
Terlipressin is already approved
Targeting improved efficacy and safety compared to IV bolus dosing

***Clinically de-risked development program
The same therapy that is currently in use in Italy and Australia

***US patent protection
through 2036

***Filed for patents in Japan,
China & Europe

***US Orphan Drug designations for
both ascites and HRS to enable 7
years of market exclusivity

***FDA Fast Track status; will seek
Breakthrough Therapy designation


https://www.biovieinc.com/wp-content/uploads/2019/01/BioVie-Non-Conf-Deck_Dec_2018.pdf

Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals

Around 20 million Americans have a progressive, life-threatening liver condition called non-alcoholic steatohepatitis (NASH), and there's isn't much doctors can do about it besides recommending fewer calories and more exercise.

Any day now, Intercept Pharmaceuticals (NASDAQ: ICPT) will share long-awaited pivotal trial results that could make its Ocaliva drug the first approved NASH treatment. The lead candidate at Madrigal Pharmaceuticals (NASDAQ: MDGL) is behind Ocaliva on the development timeline, but results so far tick all the right boxes. Let's examine the case for both stocks to decide which one is the better pick right now.
Two men in business attire are wearing boxing gloves. One has his head lowered, while the other has his arms raised in celebration.

Investigators are going to present long-awaited interim results for Intercept's only drug, Ocaliva in the first quarter. It's been five long years since midstage results sent the stock rocketing higher. A surprising 45% of patients given Ocaliva for 72 weeks showed significant NASH improvements, compared with just 21% of the placebo group.

Defining NASH is still a work in progress, but it involves liver cells that retain more lipids than they should, which causes them to balloon and become too inflamed to function properly. Since the condition progresses slowly, the FDA is willing to grant accelerated approval to the first candidate that can reduce NASH symptoms or reduce the scarring caused by long-term inflammation. Ocaliva hit both marks in its midstage study, and a repeat performance could send the stock soaring again.

The FDA approved Ocaliva in 2016 for the treatment of primary biliary cholangitis (PBC), a condition in which the immune system damages the path bile takes from liver to the stomach. Bile acids that back up into liver tissue cause all sorts of problems for an estimated 130,000 Americans with PBC, and this population needed a new treatment option.

Ocaliva is a super-potent analog of a natural bile acid, but PBC patients with seriously impaired livers should start with just 5 mg per week. More than a few patients with severe cirrhosis died after taking the recommended dosage for healthier patients, which is 5 mg every day. A more stringent risk mitigation strategy is doing its job, and sales are climbing again.

During the first nine months of 2018, Ocaliva sales rose 36% over the previous-year period to $125 million. That will help extend the company's cash runway, but not by much. Intercept's operating expenses reached $330 million during the same period.

At the end of September, the company had $489 million in cash after losing $221 million during the first nine months of 2018. If Intercept's long-awaited NASH results disappoint, raising any more cash will become nearly impossible. Beyond Ocaliva, the company doesn't have anything coming through its pipeline.
Benjamin Franklin hiding under some tablets.

This pre-commercial biotech is developing a tablet that acts on the thyroid hormone receptor beta (TRB), which seems like the right target for treating NASH. Biopsies taken during a midstage study with MGL-3196 showed that 56% of patients given the drug experienced a significant reduction of NASH symptoms after 36 weeks, compared with just 32% of the placebo group.

Madrigal's experimental treatment ticked another box by reducing fibrosis as well. If MGL-3196 can produce improvements to NASH and the fibrosis it causes in a pivotal study as well, the drug should clear the FDA's hurdles without any trouble.

Although the agency is primarily concerned with inflammation and scarring, MGL-3196 impressed investors by helping NASH patients lower liver fat content, measured with an MRI, by 37%, compared with a 9% reduction in the placebo group. Shortly after Madrigal's day in the sun, though, Viking Therapeutics (NASDAQ: VKTX) released data for its TRB agonist that showed a liver fat reduction that was much stronger, but we haven't seen any biopsy results from a Viking candidate yet.

Madrigal doesn't have a revenue stream yet, but the clinical-stage biotech is running a much smaller operation than Intercept. In fact, Madrigal licensed its only clinical-stage candidate from Roche (NASDAQOTH: RHHBY) and owes the pharma giant a single-digit royalty percentage if MGL-3196 hits pharmacy shelves. Despite a complete lack of revenue during the first nine months of 2018, Madrigal lost just $21 million during the first nine months of 2018.

Phase 2 results for MGL-3196 hit the mark last May, but Madrigal still hasn't told investors if its phase 3 study for MGL-3196 will begin before the end of 2019. Madrigal finished September with $489 million in cash, which means it can probably afford to wait for a deep-pocketed drugmaker to make a buyout offer, or at least a partnership deal.
The better buy

If trial results on the way this quarter fall in line with earlier observations, Intercept could have a gigantic addressable patient population all to itself. The NASH market probably won't stay sewn up for long. A large underserved patient population has inspired a great deal of drug development, and right now there are dozens of potential competitors in mid- to late-stage testing.

Madrigal's $2.1 billion market cap seems like a compelling bargain for a drugmaker that wants to jump into NASH with a drug ready for late-stage testing, but we'll probably have to wait until at least one proves itself in the commercial setting. Intercept's a little more expensive than Madrigal, with a recent market cap of $3.2 billion, but Ocaliva's revenue stream now, coupled with a great chance at becoming the NASH population's first treatment option, makes it the better buy at the moment.

GO MDGL

"PEACE"

Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL)
Abigail Fisher
,Insider Monkey•December 13, 2018

Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 (including dividend payments). Conversely, hedge funds’ 30 preferred S&P 500 stocks (as of June 2014) generated a return of 15.1% during the same 12-month period, with 53% of these stock picks outperforming the broader market benchmark. Coincidence? It might happen to be so, but it is unlikely. Our research covering the last 18 years indicates that hedge funds' stock picks generate superior risk-adjusted returns. That's why we believe it is wise to check hedge fund activity before you invest your time or your savings on a stock like Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL).

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) was in 26 hedge funds' portfolios at the end of September. MDGL has seen an increase in support from the world's most elite money managers of late. There were 21 hedge funds in our database with MDGL holdings at the end of the previous quarter. Our calculations also showed that MDGL isn't among the 30 most popular stocks among hedge funds.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 18 percentage points since May 2014 through December 3, 2018 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter. Even if you aren't comfortable with shorting stocks, you should at least avoid initiating long positions in our short portfolio.
Felix Baker - Baker Bros.
Felix Baker - Baker Bros.

Let's take a peek at the key hedge fund action regarding Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL).
What does the smart money think about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)?

At Q3's end, a total of 26 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 24% from one quarter earlier. Below, you can check out the change in hedge fund sentiment towards MDGL over the last 13 quarters. So, let's see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
MDGL_dec2018
MDGL_dec2018

The largest stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) was held by Baker Bros. Advisors, which reported holding $250.4 million worth of stock at the end of September. It was followed by venBio Select Advisor with a $99.1 million position. Other investors bullish on the company included Rock Springs Capital Management, Healthcor Management LP, and Point72 Asset Management.

Now, specific money managers were breaking ground themselves. Point72 Asset Management, managed by Steve Cohen, established the most valuable position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Point72 Asset Management had $20.3 million invested in the company at the end of the quarter. Steven Boyd's Armistice Capital also initiated a $17.1 million position during the quarter. The following funds were also among the new MDGL investors: Jeffrey Jay and David Kroin's Great Point Partners, Principal Global Investors's Columbus Circle Investors, and Paul Marshall and Ian Wace's Marshall Wace LLP.

Let's now take a look at hedge fund activity in other stocks - not necessarily in the same industry as Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) but similarly valued. We will take a look at Ellie Mae Inc (NYSE:ELLI), Guangshen Railway Co. Ltd (NYSE:GSH), ACI Worldwide Inc (NASDAQ:ACIW), and GATX Corporation (NYSE:GATX). This group of stocks' market valuations match MDGL's market valuation.

[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position ELLI,15,613258,2 GSH,1,4749,0 ACIW,15,298192,-2 GATX,11,267813,1 Average,10.5,296003,0.25 [/table]

View table here if you experience formatting issues.

As you can see these stocks had an average of 10.5 hedge funds with bullish positions and the average amount invested in these stocks was $296 million. That figure was $576 million in MDGL's case. Ellie Mae Inc (NYSE:ELLI) is the most popular stock in this table. On the other hand Guangshen Railway Co. Ltd (NYSE:GSH) is the least popular one with only 1 bullish hedge fund positions. Compared to these stocks Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.
https://finance.yahoo.com/news/hedge-funds-think-madrigal-pharmaceuticals-040346370.html

GO MDGL

"PEACE"

Here's Why Madrigal Pharmaceuticals Fell 39.4% in November

What happened

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL), a clinical-stage biotechnology company, fell 39.4% in November, according to data from S&P Global Market Intelligence. Madrigal presented impressive clinical trial results for its lead candidate that were overshadowed by a surprise from a potential rival.

So what

Non-alcoholic steatohepatitis (NASH) is a growing epidemic that threatens the lives of an estimated 20 million Americans at the moment, and there aren't available treatments proven to help. There's an even larger population of people with non-alcoholic fatty liver disease (NAFLD), a condition that progresses to NASH once the liver becomes inflamed and begins sustaining damage.

Nobody's quite sure what causes the immune system to begin attacking fatty livers, but reducing their overall fat content seems like a step in the right direction. Madrigal's lead candidate, MGL-3196, is a potential first-in-class treatment called a thyroid hormone receptor-beta (TRB) agonist. Trial results presented at a medical conference in November showed MGL-3196 led to a 37% average liver fat reduction for NASH patients after 36 weeks of treatment.

Unfortunately for Madrigal, Viking Therapeutics (NASDAQ: VKTX) presented results from a midstage trial with another experimental TRB agonist that's a little further back on the development timeline. Treatment with VK2809 helped NAFLD patients reduce their liver fat content by 59%, which appears to wipe the floor with results from MGL-3196.

Now what

Investors should bear in mind that the varied results don't necessarily mean one treatment is any better than the other, because they were tested different groups of patients. Viking's midstage study enrolled NAFLD patients who haven't progressed to NASH. Until we see results from a head-to-head trial or at least similar patient groups, any comparisons between VK2809 and MDGL-3196 need to be taken with a huge grain of salt.

Madrigal shareholders who have held on despite recent losses can take heart in the FDA's recent draft guidance regarding NASH drug development. The disease progresses too slowly to measure survival outcomes, so the agency's willing to consider new NASH treatments for approval if they reverse or at least control symptoms of inflammation and stiffening of liver tissue. Patients treated with MDGL-3196 were 450% more likely to experience resolution of their NASH symptoms than those given a placebo. Another performance like this in a pivotal study would almost meet the agency's criteria.
https://finance.yahoo.com/news/apos-why-madrigal-pharmaceuticals-fell-200300888.html

GO MDGL

"PEACE"

MDGL has now lost all the gains from the big bounce to $326...........Such be the way of the markets.

Meanwhile..........

Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $496,000 of Shares
[GuruFocus.com]
GuruFocus.com
,GuruFocus.com•November 20, 2018

- By insider

CEO of Madrigal Pharmaceuticals Inc (MDGL) Paul A Friedman bought 4,000 shares of MDGL on 11/19/2018 at an average price of $124 a share. The total cost of this purchase was $496,000.

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc has a market cap of $1.85 billion; its shares were traded at around $120.50 . Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years.

Warning! GuruFocus has detected 5 Warning Signs with WBA. Click here to check it out.
MDGL 15-Year Financial Data
The intrinsic value of MDGL
Peter Lynch Chart of MDGL


CEO Recent Trades:

CEO Paul A Friedman bought 4,000 shares of MDGL stock on 11/19/2018 at the average price of $124. The price of the stock has decreased by 2.82% since.

Directors and Officers Recent Trades:

Director, 10% Owner Fred B Craves bought 2,000 shares of MDGL stock on 11/19/2018 at the average price of $124.69. The price of the stock has decreased by 3.36% since.

GO MDGL

"PEACE"

Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc.
https://finance.yahoo.com/news/better-nash-stock-madrigal-pharmaceuticals-133100327.html

GO MDGL

"PEACE"

Madrigal preparing for late-stage testing of experimental NASH treatment
https://finance.yahoo.com/m/c73d29de-b484-34c1-bb50-d14f0465cc55/madrigal-preparing-for.html

GO MDGL

"PEACE"